Menu
Search
|

Menu

Close
X

Immune Pharmaceuticals Inc IMNP.OQ (NASDAQ Stock Exchange Capital Market)

0.37 USD
-0.00 (-0.99%)
As of 2:29 AM IST
chart
Previous Close 0.37
Open 0.38
Volume 94,417
3m Avg Volume 219,048
Today’s High 0.38
Today’s Low 0.36
52 Week High 5.02
52 Week Low 0.33
Shares Outstanding (mil) 10.58
Market Capitalization (mil) 15.02
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-1.460
FY16
-10.822
FY15
-18.914
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
--
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
--
16.52
LT Debt to Equity (MRQ)
vs sector
--
12.22
Return on Investment (TTM)
vs sector
-201.88
14.43
Return on Equity (TTM)
vs sector
-1,487.29
16.13

EXECUTIVE LEADERSHIP

Elliot Maza
President, Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer, Secretary, Director, Since 2017
Salary: --
Bonus: --
Anthony Fiorino
Chief Operating Officer, Chief Medical Officer, Since 2017
Salary: --
Bonus: --
John Clark
Controller, Since 2017
Salary: --
Bonus: --
Cameron Durrant
Lead Independent Director, Since 2015
Salary: --
Bonus: --
Daniel Teper
Director, Since 2017
Salary: $342,456.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

550 Sylvan Ave Ste 101
ENGLEWOOD CLIFFS   NJ   07632-3115

Phone: +1201.4642677

Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company's segment is acquiring, developing and commercializing prescription drug products. Its Immuno-inflammation product pipeline includes bertilimumab, a fully human antibody targeting eotaxin-1, a regulator of immuno-inflammation; a portfolio of immune oncology products, and NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, for the treatment of atopic dermatitis and psoriasis. Its immuno-oncology pipeline includes Ceplene, a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells.

SPONSORED STORIES